Publications
-
Modulation of Hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms.
Norman KL,
Sarnow P.
J Virol.
2009
-
MicroRNAs: expression, avoidance and subversion by vertebrate viruses.
Sarnow P,
Jopling CL, Norman KL, Schütz S, Wehner KA.
Nat Rev Microbiol.
2006;
4
(9):
651-9
-
Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122.
Jopling CL,
Norman KL, Sarnow P.
Cold Spring Harb Symp Quant Biol.
2006:
71
369-76
-
Not all viruses are bad guys: the case for reovirus in cancer therapy.
Norman KL,
Lee PW.
Drug Discov Today.
2005;
10
(12):
847-55
-
Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.
Norman KL,
Hirasawa K, Yang AD, Shields MA, Lee PW.
Proc Natl Acad Sci U S A.
2004;
101
(30):
11099-104
-
Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.
Yang WQ,
Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA.
Gene Ther.
2004;
11
(21):
1579-89
-
Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic.
Loken SD,
Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ.
Cancer Biol Ther.
2004;
3
(8):
734-8
-
Systemic reovirus therapy of metastatic cancer in immune-competent mice.
Hirasawa K,
Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW.
Cancer Res.
2003;
63
(2):
348-53
-
Reovirus oncolysis of human breast cancer.
Norman KL,
Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW.
Hum Gene Ther.
2002;
13
(5):
641-52
-
Oncolytic reovirus against ovarian and colon cancer.
Hirasawa K,
Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW.
Cancer Res.
2002;
62
(6):
1696-701
-
Oncolytic viruses and cancer therapy.
Norman KL,
Farassati F, Lee PW.
Cytokine Growth Factor Rev.
2001 Jun-Sep;
12
(2-3):
271-82
-
Reovirus as a novel oncolytic agent.
Norman KL,
Lee PW.
J Clin Invest.
2000;
105
(8):
1035-8
Help